For the Inventor, By the Inventor

Enter assignee name

Madison, NJ, United States of America

Vitae Pharmaceuticals, Inc.

USPTO Granted Patents = 85

CIPO Patents = 4

EPO Patents = 38

Trademarks = 3

Forward Citations = 366

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Suresh B Singh (67 out of 74 patents)

David A Claremon (58 out of 147 patents)

Linghang Zhuang (54 out of 65 patents)

4. Colin M Tice (53 out of 68 patents)

5. Wei Zhao (41 out of 53 patents)

6. Jing Yuan (40 out of 56 patents)

7. Lawrence Wayne Dillard (38 out of 64 patents)

8. Yajun Zheng (33 out of 38 patents)

9. Zhenrong Xu (32 out of 38 patents)

10. Salvacion Cacatian (32 out of 33 patents)

11. Lanqi Jia (30 out of 31 patents)

12. Yi Fan (26 out of 28 patents)

13. Stephen D Lotesta (26 out of 26 patents)

14. Katerina Leftheris (26 out of 89 patents)

15. Yuanjie Ye (24 out of 25 patents)

Core Competencies:

Menin-MLL Interaction

ROR-Gamma Inhibitors

Beta-Secretase Inhibitors

Liver X Receptor Modulators

Dihydropyrrolopyridine Compounds

Isoindoline Inhibitors

Thiazolopyrrolidine Inhibitors

Cyclic Urea Inhibitors

Substituted Heterocycles

11β-Hydroxysteroid Dehydrogenase Inhibitors

Benzimidazole Derivatives

Piperazine Derivatives

85 patents: Sort by Forward Citations

1. 12312359 - Inhibitors of the menin-MLL interaction (2025-05-27),

2. 11919901 - Inhibitors of the menin-MLL interaction (2024-03-05),

3. 11739085 - Inhibitors of the menin-MLL interaction (2023-08-29),

4. 11535614 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2022-12-27),

5. 11479557 - Inhibitors of the menin-MLL interaction (2022-10-25),

6. 11186573 - Inhibitors of ROR gamma (2021-11-30),

7. 11008340 - Modulators of ROR-gamma (2021-05-18),

8. 11001583 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2021-05-11),

9. 10899758 - Inhibitors of the menin-MLL interaction (2021-01-26),

10. 10829481 - Benzimidazole derivatives as modulators of ROR-gamma (2020-11-10),

11. 10829448 - Substituted benzoimidazoles as modulators of ROR-γ (2020-11-10),

12. 10807980 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2020-10-20),

13. 10683302 - Inhibitors of the menin-MLL interaction (2020-06-16),

14. 10399976 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2019-09-03),

15. 10336717 - Inhibitors of beta-secretase (2019-07-02),

Vitae Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs for the treatment of serious diseases. By leveraging our proprietary structure-based drug discovery platform, we aim to rapidly identify and optimize potential drug candidates. Our scientific expertise lies in the fields of immunology, oncology, and metabolic diseases. We are committed to improving patients' lives by advancing innovative therapies and addressing unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

85 Patents

#7 in Madison, NJ

#195 in New Jersey

#4,219 in US

#8,664 in the World

Madison, NJ, United States of America

Vitae Pharmaceuticals, Inc.

Forward Citations = 366

62 inventors:

Suresh B Singh (67 out of 74 patents)

David A Claremon (58 out of 147 patents)

Linghang Zhuang (54 out of 65 patents)

4. Colin M Tice (53 out of 68 patents)

5. Wei Zhao (41 out of 53 patents)

Please report any incorrect information to support@idiyas.com

Loading…